Oral available agents in the treatment of relapsing remitting multiple sclerosis an overview of merits and culprits
Open Access
- 1 February 2013
- journal article
- Published by Informa UK Limited in Drug, Healthcare and Patient Safety
- Vol. 5, 37-47
- https://doi.org/10.2147/DHPS.S28822
Abstract
Multiple sclerosis (MS) is a chronic immunological disease of the central nervous system characterized by early inflammatory demyelination and subsequent neurodegeneration. Major therapeutic progress has occurred during the past decade, in particular since the introduction of immunomodulatory agents, however, MS is still an incurable disease. In addition, parenteral application of the currently licensed drugs is associated with injection-related adverse events (AEs) and low patient compliance. Thus, there remains an unmet need for the development of more effective and well tolerated oral therapies for the treatment of MS. A number of new orally administered agents including fingolimod, laquinimod, teriflunomide, cladribine, and BG-12 have been licensed recently or are currently under investigation in relapsing remitting MS patients. In multi-center, randomized, placebo-controlled phase III clinical studies, all of these agents have already shown their efficacy on both clinical disease parameters and magnetic resonance imaging-based measures of disease activity in patients with relapsing remitting MS. However, there are essential differences concerning their clinical efficacy and side-effect profiles. Additionally, the mechanisms by which these substances exert clinical efficacy have not been fully elucidated. In this article, we review the pharmaceutical properties of fingolimod, laquinimod, teriflunomide, cladribine, and BG-12; and their suggested mechanisms of action, clinical efficacy, and side-effect profiles.Keywords
This publication has 38 references indexed in Scilit:
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple SclerosisNew England Journal of Medicine, 2012
- Multiple sclerosisThe Lancet, 2008
- Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyThe Lancet, 2008
- Oral Fingolimod (FTY720) for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Oral fumaric acid esters for the treatment of active multiple sclerosis: an open‐label, baseline‐controlled pilot studyEuropean Journal of Neurology, 2006
- Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-β k.o. and wild type miceJournal of Neuroimmunology, 2006
- A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapsesNeurology, 2006
- Cladribine for multiple sclerosis: review and current statusExpert Review of Neurotherapeutics, 2005
- Treatment with laquinimod reduces development of active MRI lesions in relapsing MSNeurology, 2005
- Cladribine in treatment of chronic progressive multiple sclerosisThe Lancet, 1994